The Size of the Renal Biomarkers Market in Europe is valued at USD xx million in 2019 and estimated to grow at a CAGR of xx.x%, to reach USD xx million by 2024 during the forecast period 2019 - 2024.
A Renal Biomarkers indicates the presence of kidney diseases by measuring blood or urine levels. Kidney diseases are one of the main reasons for death around the world. The incidence of Chronic kidney diseases have increased due to factors like diabetes and hypertension. Advancements in technology have led to the introduction of renal biomarker which detects kidney problems accurately.
The significant drivers are rising population with kidney problems, growing incidence of renal diseases, increasing geriatric population and increasing incidence of diseases like high blood pressure and diabetes. Advancements in technology is also expected to drive the market over the forecast period. Reimbursement issues are major restraints limiting this industry.
Europe Renal Biomarkers Market has been segmented and sub-segmented into the following categories
On the basis of region, Europe is assumed as a developed market and is anticipated to witness significant growth in the forecast period.
Prominent Companies dominating the Europe Renal Biomarkers Market Profiled in the Report are Abbott Diagnostics, F. Hoffmann-La Roche AG, Beckman Coulter Inc., Astute Medical Inc., Siemens Healthcare Diagnostics Inc., Thermo Fisher Scientific Inc., Alere Inc., bioMérieux SA, and Randox Laboratories Ltd.,
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemiology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Diagnostic Technique
5.1.1 Introduction
5.1.2 Chemiluminescent Enzyme Immunoassay
5.1.3 Colorimetric Assay
5.1.4 Enzyme-Linked Immunosorbent Assay
5.1.5 Liquid Chromatography-Mass Spectrometry
5.1.6 Particle-Enhanced Turbidimetric Immunoassay
5.1.7 Y-o-Y Growth Analysis, By Diagnostic Technique
5.1.8 Market Attractiveness Analysis, By Diagnostic Technique
5.1.9 Market Share Analysis, By Diagnostic Technique
5.2 Type
5.2.1 Introduction
5.2.2 Up-Regulated Proteins
5.2.2.1 Interleukin 18
5.2.2.2 Kidney injury molecule 1
5.2.2.3 Neutrophil gelatinase-associated lipocalin
5.2.3 Functional Biomarker
5.2.3.1 Serum Creatinine
5.2.3.2 Serum Cystatin C
5.2.3.3 Urine Albumin
5.2.4 Others
5.2.5 Y-o-Y Growth Analysis, By Type
5.2.6 Market Attractiveness Analysis, By Type
5.2.7 Market Share Analysis, By Type
5.3 End User
5.3.1 Introduction
5.3.2 Diagnostic Labs
5.3.3 Hospitals
5.3.4 Outpatient Clinics
5.3.5 Research Centres
5.3.6 Y-o-Y Growth Analysis, By End User
5.3.7 Market Attractiveness Analysis, By End User
5.3.8 Market Share Analysis, By End User
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Diagnostic Technique
6.1.3.3 By Type
6.1.3.4 By End User
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Diagnostic Technique
6.1.4.3 By Type
6.1.4.4 By End User
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Diagnostic Technique
6.1.5.3 By Type
6.1.5.4 By End User
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
6.7 Rest of Europe
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Thermo Fisher Scientific Inc
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Abbott Laboratories
8.3 Beckman Coulter, Inc.
8.4 Randox Laboratories Ltd
8.5 Astute Medical Inc.
8.6 F. Hoffmann-La Roche AG
8.7 Siemens Healthcare Diagnostics Inc.
8.8 Alere Inc.
8.9 bioMérieux SA
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, Collaborations, and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
